臺灣博碩士論文加值系統

本研究的目的是調查台灣地區的犬紅斑性狼瘡(canine systemic lupus erythematosus, canine SLE)及探討環境因子對犬SLE之影響。我們篩檢台灣地區1325隻家犬，其中包括SLE病人所飼養之44隻家犬。以間接免疫螢光染色法(indirect immunofluorescent assay, IFA)檢測血清之抗核抗體(antinuclear antibodies, ANA)，於所篩檢1281隻一般家犬中，有33隻為ANA陽性，陽性率為2.6％，另一方面在SLE病人所飼養之44隻家犬中，有3隻為ANA陽性，陽性率為6.8％。此結果顯示SLE病人所飼養之家犬的ANA陽性率比一般家犬高。這些ANA陽性血清在IFA染色時，以呈現斑點(speckled)核型為主，佔63.8％ (23/36)；其次為細斑點(fine speckled)核型，佔22.2％ (8/36)。依據1999年Chabanne等修改人類SLE的11項診斷標準，所訂立之犬SLE診斷標準，凡符合其中4項或更多項者可判定為SLE，於1325隻犬中有4隻判定為SLE病犬，盛行率為0.30％，較美國地區之犬SLE盛行率0.027％高出許多。我們以西方墨漬法(western analysis)分析36隻ANA陽性犬之抗核抗體所識別的抗原，抗Sm抗體比率為16.7％、抗G型核內異質核糖核蛋白(heterogeneous nuclear ribonucleoprotein G, hnRNP G) 抗體比率為75％、抗謝格連氏症B型抗原(Sjogren''s syndrome type B antigen, SS-B)抗體比率為41.7％、抗謝格連氏症A型抗原(Sjogren''s syndrome type A antigen, SS-A)抗體比率為36.1％、抗U1-70K抗體有66.7％，其中hnRNP G是SLE病犬抗核抗體所辨識之特異性抗原。在SLE的傳染因子研究方面，EB病毒(Epstein-Barr virus, EBV)目前被懷疑是引發人類SLE之環境或傳染因子之一。我們以西方墨漬法檢測32隻ANA陽性犬(含4隻SLE病犬)及44隻健康犬血清之抗EBV抗體，結果顯示4隻SLE病犬均有抗EBV抗體，陽性率為100％。與此相較，ANA陽性犬有92.9％ (26/28)、健康犬則只有88.6％ (39/44)具有抗EBV抗體。其中抗EBNA-1抗體陽性率之差異如下：在SLE病犬為100％ (4/4)，ANA陽性犬為59.4％ (19/32)，健康犬為22.7％ (10/44)。EBV在犬隻感染情形及其與SLE之關聯如何，亟待深入去探討。

The goals of this study are to investigate the prevalence of canine systemic lupus erythematosus (SLE), and to study the development of environmental factor on canine SLE in Taiwan. In this study, 1325 canine sera were collected in Taiwan, including 44 pet dogs owned by SLE patients. The presence of antinuclear antibodies (ANA) was determined by indirect immunofluorescent assay (IFA). Among 1281 canine sera screened from general population, 33 were positive for ANA (2.6%). On the other hand, among 44 serum samples from pet dogs owned by patients with SLE, 3 samples were ANA positive (6.8%). These results indicated that the ratio of ANA positive sera from pet dogs owned by SLE patients was higher than that of other dogs. These ANA primarily presented with the speckled (63.8%) or the fine speckled (22.2%) nuclear staining patterns by IFA. According to the canine SLE diagnosis criteria, which were revised from the diagnosis criteria of human SLE by Chabanne in 1999, a dog that fulfills any 4 or more of the 11 criteria can be diagnosed as canine SLE. We concluded that 4 in 1325 dogs could be diagnosed as canine SLE. The prevalence of canine SLE in Taiwan was 0.30%, which was signficantly higher than that (0.027%) in USA. By western analysis, we identified the nuclear antigens that could be recognized by ANA. Among 36 ANA positive canine sera, the percentages were 16.7% for anti-Sm antibody, 75% for anti-heterogeneous nuclear ribonucleoprotein G (hnRNP G) antibody, 41.7% for anti-Sjogren''s syndrome type B antigen (SS-B) antibody, 36.1% for anti-Sjogren''s syndrome type A antigen (SS-A), and 66.7% for anti-U1-70K antibody. Among these nuclear antigens, hnRNP G is the specific antigen recognized by ANA of SLE dogs. Epstein-Barr virus (EBV) is recently suspected as one of the environmental agents that could induce human SLE. Therefore, we examined the anti-EBV antibodies present in the sera of 32 ANA positive (4 SLE dogs included) and 44 healthy dogs by western analysis. The results indicated that all of the SLE dogs (100% or 4/4) had anti-EBV antibodies. In contrast, 92.9% (26/28) of ANA positive dogs, and 88.6% (39/44) of healthy dogs had seroconverted against EBV. The percentages of anti-EBNA-1 antibodies were 100% (4/4) for SLE dogs, 59.4% (19/32) for ANA positive dogs, and 22.7% (10/44) for healthy dogs. It remains to be determined whether EBV can indeed infect dogs and further associate with SLE.

目錄...................................................................................................Ⅰ
表次...................................................................................................Ⅱ
圖次...................................................................................................Ⅲ
縮寫表...............................................................................................Ⅳ
中文摘要...........................................................................................Ⅴ
英文摘要...........................................................................................Ⅵ
第一章 緒言.......................................................................................1
第二章 文獻探討...............................................................................2
第一節 臨床病徵及診斷標準................................................. 3
第二節 抗核抗體.................................................................... .4
第三節 紅斑性狼瘡病因........................................................ 12
第三章 材料與方法..........................................................................20
第四章 結果......................................................................................25
第五章 討論......................................................................................29
參考文獻............................................................................................50

蔡寧遠。1997。家犬紅斑性狼瘡自體免疫抗體之研究。碩士論文。國立中興大學獸醫學研究所。台中。中華民國。
Adames, L. E., and E. V. Hess. 1991. Drug related lupus: incidence, mechanism and clinical implication. Drug safety. 6:431.
Agnello, V. 1978. Association of systemic lupus erythematosus and SLE-like syndromes with hereditary and acquired complement deficiency states. Arthritis Rheum. 21:S146-S152.
Aheran, J. M., T. P. Thomas, A. D. Carole, B.S. Mary, B. B. Wilma and C.A. Frank. 1982. Interrelationships of HLA-DR, MB, and MT phenotypes, autotantibody expression, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 25:1031-1040.
Ait-Kaci, A., J. C. Monier, and N. Mamelle. 1981. Enzyme linked immunosorbent assay for antihistone antibodies and their presence in systemic lupus erythematosus sera. J. Immunol. Methods 44:311-322.
Alarcon-Segovia, D., K. G. Wakim, J. W. Worthington, and L.E. Ward. 1967. Clinical and experimental studies of the hydralazine syndrome and its relationships to systemic lupus erythematosus. Med. (Baltimore) 46:1-33.
Anderson, S.T., and E. C. Klein. 1993. Systemic lupus erythematosus in a Rhesus macaque. Arthritis Rheum. 36:1739-1742.
Balazs, T., C. J. G. Robinson, and N. Balter. 1981. Hydralazine-induced antinuclear antibodies in Beagle dogs. Toxicol. Applied Pharmacol. 57:452-456.
Beaucher, W.N., R. H. Garman, and J. J. Condemi. 1977. Familial lupus erythematosus antibodies to DNA in household dogs. N. Eng. J. Med. 296:982-984.
Bencze, G., L. Lakatos, and M. Ludanyi. 1960. Two types of lupus erythematosus cell factor, shown by induced LE cell phenomenon in dog. Brit. Med. J. 1:1707-1709.
Bennett, D., and D. Kirkham. 1987. The laboratory identification of serum antinuclear antibody in the dog. J . Comp. Pathol. 97:523-539.
Bernstein, R. M., R. N. Hobbs, D. J. Lea, D. J. Ward, and G. R. V. Hughes.1985. Patterns of antihistone antibody specificity in systemic lupus erythematosus. Arthritis Rheum. 28:285-293.
Block, S. R., J. B. Winfield, M. D. Lockshin, W. A. D. Angelo, and C. L.
Christian. 1975. Studies of twins with systemic lupus erythematosus. Am. J.
Med. 59:533-552.
Boyer, C. N., R. A. Eisenberg and P. L. Cohen. 1985. Quantitation of the Sm nuclear antigen in tissues and activated lymphocytes. Arthritis Rheum. 28:294-299.
Brand, A., D.J. Griffiths, C. Herve, E. Mallon, and P. J. Venables. 1999. Human retrovirus in rheumatic disease. J. Autoimmunity. 13:149-154.
Brinet, A., C. Fournel, J. R. Faure, C. Venet, and J. C. Monier. 1988. Anti-
histone antibodies (ELISA and immunoblot) in canine lupus erythematosus.
Clin. Exp. Immunol. 74:105-109.
Brinkman, K., and R. M. Termat. 1990. Anti-DNA antibodies and lupus
nephritis: the complexity of cross reactivity. Immunol. Today 11:232-234.
Carpenter, J. R., F. C. Mcduffie, and S. G. Sheps. 1980. Prospective study of immune-response to hydralazine and development of antideoxyribonucleoprotein in patients receiving hydralazine. Am. J. Med. 69:395.
Chabanne, L., C. Fournel, J. C. Monier, and D. Rigal. 1999a. Canine systemic lupus erythematosus. Part I. Clinical and biological aspects. Compend. Contin. Educ. Pract. Vet. 21:135-141.
Chabanne, L., C. Fournel, J. C. Monier, and D. Rigal. 1999b. Canine systemic lupus erythematosus. Part II. Diagnosis and treatment. Compend. Contin. Educ. Pract. Vet. 21: 402-411.
Chou, C. T, D. M. Chang, C. F. Lee, and M. H. Liang. 1994. Prevalence of rheumatic diseases in Taiwan : A population study of urban, suburban, rural differences. Rheumatol. 21: 302-306.
Chow, K.C., J. Ma, L. S. Lin, K. H. Chi, S. H. Yen, S. M. Liu, W. T. Liu, W. K. Chen, T.H. Chang, and K.Y. Chen.1997a. Serum response to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma : complementaly test of EBNA-1 and EA-D. Cancer Epidemiology, Biomarker & Prevention. 6:363-368.
Chow, K.C., J. X. Zhang, S. Chow, W. S. Tseng, K.Y. Chen. 1997b. Appliction of viral examination in the diagnosis and therapy of tumors. Therapentic Radiology and Oncology. 4:155-178.
Clair, D., R. J. Dehoratius, J. Wolfe and R. Halliwell. 1980. Autoantibodies in human contacts of SLE dogs. Arthritis Rheum. 23:251-253.
Comens, P. 1956. Experimental hydralazine disease and its similarity to disseminated lupus erythematosus. J. Lab. Clin. Med. 471:444-454.
Costa, C., and J. C. Monier. 1986. Antihistone antibodies detected by ELISA and immunoblotting in systemic lupus erythematosus and Rheumatoid Arthritis. J. Rheumatol. 13:722-725.
Costa, O., E. Fournel, E. Lotchouang, J. C. Monier, and M. Fontaine. 1984. Specificities of antinuclear antibodies detected in dogs with systemic lupus erythematosus. Vet. Immunol. Immunopathol.7:369-382.
Craft, J. 1992. Antibodies to snRNPs in systemic lupus erythematosus. Rheum. Dis. Clin. North. Am. 18:311-335.
Crowe, W., and I. Kusher. 1977. An immunofluorescent method using Crithidia luciliar to detect antibodies to double-stranded DNA. Arthritis Rheum. 20:811-814.
Dausset, J., J. Colombani, and M. Colombani. 1961. Study of leukopenias and thrombocytopenias by the direct antiglobulin consumption test on leukocytes and platelets. Blood 18:672-690.
Dardari, R., M. Khyatti, A. Benider, H. Jouhadi, A. Kanlain, and C. Cochet. 2000. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. Int. J. Cancer. 85:71-75.
Day, M. J., P.H. Kay, W. T. Clark, S. E. Shaw, W. J. Penhale, and R. L. Dawkins. 1985. Complement C4 allotype association with and serum C4 concentration in autoimmune disease in the dog, Clin. Immunol. Immunopathol. 35:85-91.
Deapen, D., A. Escalante, L. Weinrib, D. Horwitz, B. Bachman, P. Roy-Burman, A. Walker, and T. M. Mack. 1992. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 35:311-318.
Drazer, F. H. 1980. Systemic lupus erythematosus in the dog. Com. Cont. Ed. 3: 156-162.
Dubroff, L. M, and R. J. Reid. 1980. Hydralazine-pyrimidine interactions may explain hydralazine-induce lupus erythematosus. Science. 208: 404-406.
Dubois, E. L., and D. L. Tuffanelli. 1964. Clinical manifestations of systemic lupus erythematosus computer analysis of 520 cases. J. Am. Med. Assoc. 190:104-111.
Fessel, W. J. 1988. Epidemiology of systemic lupus erythematosus. Rheuma. Dis. Clin. N. Am. 14:15-23.
Field, E. M. and H. S. Peter. 1983. Antibodies to Sm and RNP. Arthritis Rheum. 26:848-853.
Fournal, C, L. Chabanne, C. Caux, and J. C. Monier. 1992. Canine systemic lupus erythematosus. I: A study of 75 cases. Lupus. 1: 133-9.
Friedman, S. M, J. R. Tumang, and M. K. Crow. 1993. Microbial superantigens as etiopathogenic agents in autoimmunity. Rheum Dis Clin North Am.19: 207-222.
Fye, K. H., and K. E. Sack. 1991. Rheumatic disease. In: Basic and Clinical Immunlolgy. Appleton and Lange, East Norwalk, CN, pp. 438-463.
Gabber, N. H. 1983. Systemic lupus erythematosus in a cat with thrombocypenia. Vet. Med. Small. Amin. Clin. 78:77-79.
Gardner, D. L. 1957. The respones of the dog to oral 1-hydrazinophthalazine (hydralazine). Brit. J. Wxp. Pathol. 38:227-235.
Geor, R.J., E.G. Clark, D. M. Haines, and P. G. Napier. 1990. Systemic lupus erythematosus in a filly. J. Am. Vet. Med. Assoc. 197 : 1489-1492.
Gibofsky, A. M, R. J. Winchester, M. Patarroyo, M. Fatino, and H. G. Kunkel. 1978. Diseases association of the La-like human alloantigens: contrasting patterns in rheumatoid arthritis and systemic lupus erythematosus. J. Exp. Med. 148: 1728-1732.
Gioud, M., M. Ait-Kaci, and J. C. Monier. 1982. Histone antibodies in systemic lupus erythematosus. Arthritis Rheum. 25:407-413.
Gohill, J., and M. J. Fritzler. 1987. Antibodies in procainamide-induced systemic lupus erythematosus bind the C-terminus of histone 1. Mol. Immunol. 24:275.
Gottlieb, E., and J. A. Steitz. 1989. The RNA binding protein La influences both the accuracy and the efficiency of RNA polymerase III transcription in vitro. EMBO J. 8:841-850.
Grinderm, C. B, K. H. Johnson. 1983. Systemic lupus erythematosus: Literature review and report of 42 new cases. JAAHA. 19: 489-503.
Gutierrez, M. A., J. F. Molina, L. J. Jara, M. L. Cuelluar, C. Garcia, S. Gutierrez-Urena, A. Gharavi and L. R. Espinoza. 1995. Prolactin and systemic lupus erythematosus: prolactin secretion by SLE lymphocytes and proliferative (autocrine) activity. Lupus 4:348-352.
Habets, W. J., D. J. Rooij, M. H. Salden, A. P. Verhagen, C. A. VanEckelen, L. A. Van Deputte, and W. J. Van Venrooij. 1983. Antibodies against distinct nuclear matrix proteinsare characteristic for mixed connective tissue disease. Clin. Exp. Immunolo. 54:265-276.
Halliwell, R. E. W. 1978. Autoimmune disease in the dog. Advances in Vet. Science Comp. Med. 22:221-263.
Halliwel, R. E. W., and N. T. Gorman. 1989. Autoimmune blood diseases. In: Veterinary Clinical Immunlolgy. W. B. Saunders, Philadelphia, PA, USA. pp. 308-336.
Hardin, J. A. and J. O. Thomas. 1983. Antibodies to histones in systemic lupus erythematosus: Localization of prominent autoantigens on histones H1 and H2B. Proc. Natl. Acad. Sci. USA 80:7410.
Harly, J. B, and R. H. Scofield. 1991. Sytemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology. J. Clin. Immunol. 11: 297-316.
Harmon, C. E., J. S. Deng, C. L. Peebles, and E. M. Tan. 1984. The importance of tissue substrate in the SS-A/Ro antigen- antibody system. Arthritis Rheum. 27:166-173.
Harmon, C. E. 1985. Antinuclear antibodies in autoimmune disease: significance and pathogenicity. Med. Clin. N. Am. 69:547-563.
Hemauer, A., K. Beckenlehner, H. Wolf, and B. Lang, S. Modrow. 1999. Acute parpovirus B 19 infection in connection with a flare of systemic lupus erythematosus in a female patient. J. Clin. Virol. 14:149-154.
Hess, W. V., and Y. Farthey. 1994. Epidemiology, etiololgy, and environmental relationships of systemic lupus erythematosus. Current Opinion in Rheumatol. 6:474-480.
Hishimoto, H., H. Tsuda, and T. Matsumoto. 1985. HLA antigens associated with systemic lupus erythematosus in Japan. J. Rheumatol. 12:919-923.
Holborow, E. J. 1978. Rheumatoid factors and antinuclear antibodies. In: Copeman''s textbook of the rheumatic disease. J. T. Scott ed. Churchill, Livingstone, Edinburgh.
Holborow, E., D. Weir, and G. Johnson. 1957. A serum factor in L. E. with affinity for tissue nuclei. Br. Med. J. 1:732-734.
Holman, H., H. Deicher, and H. Kumkel. 1959. The LE cell and LE serum factor. Bull. N. Y. Acad. Med. 35:409-418.
Horwitz, D. A. and C. O. Jacob. 1994. The cytokine network in the pathogensis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin. Immunopathol. 16:181-200.
Hubert, B., M. Teichner, C. Fournel, and J. C. Monier. 1988. Spontaneous familial systemic lupus erythematosus in a canine breeding colony. J. Comp. Pathol. 98:81-89.
Incaprera, M., I. Rind; A. Bazzichi, and C. Garzelli, 1998. Potential role of the EBV in SLE autoimmunty. Clin. Experi. Rhenmatol. 16: 289-94.
James, J. A., K. M. Kaufman, A. D. Farris, E. Tayer-Albert, T. J. A. Lehman, and J.B. Harley. 1997. An increased prevalence of Epstein-Barr virus infection in young patient suggests a possible etiology for systemic lupus erythematosus. J. Clin. Invest. 100:3019-3026.
Joe, C. 1992. Antibodies to snRNPs in systemic lupus erythematosus. Rheum Dis Clin Nor Am. 18: 311-335.
Jones, D. R. E. 1993. Canine systemic lupus erythematosus: new insights and their implications. J. Comp. Pathol. 180:215-218.
Jones, S. K. 1992a. Ultraviolet radiation (UVR) induces cell- surface Ro/SS-A antigen expression by human keratinocytes in vitro: a possible mechanism for UVR induction of cutaneous lupus lesions. Br. J. Dermatol. 126:546-553.
Jones, D. R. E., N. D. Hopkinson, and R. J. Powell. 1992b. Autoantibodies in pet dogs owned by patients with systemic lupus erythematosus. Lancet 339: 1378-1380.
Kanda, N., T. Tsuchida, and K. Tamaki. 1999. Estrogen enhancement of anti-dsDNA antibodies and IgG production in peripherial blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 42:328-337.
Kaposi, M. 1872. Lupus erythematosus. Arch. Dermatol. Syphilol. 4:36-78.
Kass, P. H., R. B. Farrer, D. R. Strombeck, and A. A. Ardans. 1985. Application of long-linear and logistic regression models in the predication of systemic lupus erythematosus in the dogs. Am. J. Vet. Res. 46: 2340-2345.
Kimberly, R. P., M. D. Lockshin, R. L. Shermans, J. M. Mouradian, and S. Saal. 1983. Reversible "end-stage" lupus nephritis analysis of patients able to discontinue dialysis. Am. J. Med. 74:361-368.
Kontantinov, K., V. Russanova, and V. Russeva. 1986. Antibodies to histones and disease activity in systemic lupus erythematosus: a comparative study with an ELISA and immunoblotting. Arch. Dermatol. Res. 278: 410.
Kou, S., T.Yoshida, H. Furya, F. Kayama, E. K. L. Chen, 1998. Estrogenxenobiotics increase expression of SS-A/Ro autoantigens in cultured human epidermal cells. Acta Derm. Venerol. 78:420-423.